Position in GUTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$77,173
-$282,527 QoQ
Shares Held
168,500
+3.1% QoQ
Ownership
0.106%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cerity Partners LLC holds $355,640,511 across 116 Biotechnology names. GUTS ranks #93 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
296,654 | $132,467,876 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
43,972 | $33,974,525 | |
| 3 | CORT |
Corcept Therapeutics Inc
|
731,689 | $29,494,383 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
349,137 | $22,564,723 | |
| 5 | INCY |
Incyte Corp
|
226,501 | $21,318,272 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
263,389 | $14,878,843 | |
| 7 | EXEL |
Exelixis, Inc.
|
313,945 | $13,465,100 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
45,746 | $8,648,280 |
All Filings in GUTS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $77,173 | 168,500 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $359,700 | 163,500 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $21,569 | 13,566 | Shares | Sole | 2025-10-22 | |
| 2025-06-30 | $29,947 | 18,486 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $16,335 | 13,727 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $22,660 | 11,000 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $27,830 | 11,000 | Shares | Sole | 2024-11-12 | |
| No filing history on record for this holder in this stock. | ||||||